Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A gynecologic oncology group trial

Maurie Markman, John A. Blessing, Koenraad De Geest, Mark Morgan, Katherine Y. Look, Thomas J. Herzog, Peter G. Rose

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background. The aim of this study was to evaluate the efficacy of a more convenient topotecan administration schedule in the second-line treatment of advanced platinum-refractory ovarian cancer. Methods and materials. The Gynecologic Oncology Group conducted a Phase II trial of 24-h infusional topotecan (8.5 mg/m2), repeated every 3 weeks in 26 patients with platinum- refractory ovarian cancer (failure to respond to initial platinum-based treatment or development of recurrent disease within 6 months of completion of chemotherapy). Results. Grade 4 neutropenia (85% of patients) and thrombocytopenia (12%) were the major toxicities encountered. Of the 25 patients evaluable for response, only a single patient experienced an objective response (4%). Conclusions. When employed at this dose and schedule (24-h infusion every 3 weeks), topotecan has minimal second-line activity in platinum-refractory ovarian cancer.

Original languageEnglish (US)
Pages (from-to)444-446
Number of pages3
JournalGynecologic Oncology
Volume75
Issue number3
DOIs
StatePublished - Dec 1999
Externally publishedYes

Fingerprint

Topotecan
Platinum
Ovarian Neoplasms
Appointments and Schedules
Neutropenia
Thrombocytopenia
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer : A gynecologic oncology group trial. / Markman, Maurie; Blessing, John A.; De Geest, Koenraad; Morgan, Mark; Look, Katherine Y.; Herzog, Thomas J.; Rose, Peter G.

In: Gynecologic Oncology, Vol. 75, No. 3, 12.1999, p. 444-446.

Research output: Contribution to journalArticle

Markman, Maurie ; Blessing, John A. ; De Geest, Koenraad ; Morgan, Mark ; Look, Katherine Y. ; Herzog, Thomas J. ; Rose, Peter G. / Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer : A gynecologic oncology group trial. In: Gynecologic Oncology. 1999 ; Vol. 75, No. 3. pp. 444-446.
@article{6b14f803bc664109a2e0392914e18f02,
title = "Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A gynecologic oncology group trial",
abstract = "Background. The aim of this study was to evaluate the efficacy of a more convenient topotecan administration schedule in the second-line treatment of advanced platinum-refractory ovarian cancer. Methods and materials. The Gynecologic Oncology Group conducted a Phase II trial of 24-h infusional topotecan (8.5 mg/m2), repeated every 3 weeks in 26 patients with platinum- refractory ovarian cancer (failure to respond to initial platinum-based treatment or development of recurrent disease within 6 months of completion of chemotherapy). Results. Grade 4 neutropenia (85{\%} of patients) and thrombocytopenia (12{\%}) were the major toxicities encountered. Of the 25 patients evaluable for response, only a single patient experienced an objective response (4{\%}). Conclusions. When employed at this dose and schedule (24-h infusion every 3 weeks), topotecan has minimal second-line activity in platinum-refractory ovarian cancer.",
author = "Maurie Markman and Blessing, {John A.} and {De Geest}, Koenraad and Mark Morgan and Look, {Katherine Y.} and Herzog, {Thomas J.} and Rose, {Peter G.}",
year = "1999",
month = "12",
doi = "10.1006/gyno.1999.5640",
language = "English (US)",
volume = "75",
pages = "444--446",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer

T2 - A gynecologic oncology group trial

AU - Markman, Maurie

AU - Blessing, John A.

AU - De Geest, Koenraad

AU - Morgan, Mark

AU - Look, Katherine Y.

AU - Herzog, Thomas J.

AU - Rose, Peter G.

PY - 1999/12

Y1 - 1999/12

N2 - Background. The aim of this study was to evaluate the efficacy of a more convenient topotecan administration schedule in the second-line treatment of advanced platinum-refractory ovarian cancer. Methods and materials. The Gynecologic Oncology Group conducted a Phase II trial of 24-h infusional topotecan (8.5 mg/m2), repeated every 3 weeks in 26 patients with platinum- refractory ovarian cancer (failure to respond to initial platinum-based treatment or development of recurrent disease within 6 months of completion of chemotherapy). Results. Grade 4 neutropenia (85% of patients) and thrombocytopenia (12%) were the major toxicities encountered. Of the 25 patients evaluable for response, only a single patient experienced an objective response (4%). Conclusions. When employed at this dose and schedule (24-h infusion every 3 weeks), topotecan has minimal second-line activity in platinum-refractory ovarian cancer.

AB - Background. The aim of this study was to evaluate the efficacy of a more convenient topotecan administration schedule in the second-line treatment of advanced platinum-refractory ovarian cancer. Methods and materials. The Gynecologic Oncology Group conducted a Phase II trial of 24-h infusional topotecan (8.5 mg/m2), repeated every 3 weeks in 26 patients with platinum- refractory ovarian cancer (failure to respond to initial platinum-based treatment or development of recurrent disease within 6 months of completion of chemotherapy). Results. Grade 4 neutropenia (85% of patients) and thrombocytopenia (12%) were the major toxicities encountered. Of the 25 patients evaluable for response, only a single patient experienced an objective response (4%). Conclusions. When employed at this dose and schedule (24-h infusion every 3 weeks), topotecan has minimal second-line activity in platinum-refractory ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0032763429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032763429&partnerID=8YFLogxK

U2 - 10.1006/gyno.1999.5640

DO - 10.1006/gyno.1999.5640

M3 - Article

C2 - 10600304

AN - SCOPUS:0032763429

VL - 75

SP - 444

EP - 446

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -